The BJP has accused the AAP government of indecision on implementing the Health Information Management System (HIMS) in Delhi ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers is revolutionizing telehealth and wellness for millennials and Gen Z with rapid revenue growth and positive net ...

TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Buy rating on the shares. The firm said HIMS has ample opportunities to grow weight loss as a ...

Bearish flow noted in Hims and Hers Health with 30,788 puts trading, or 9x expected. Most active are Dec-24 21 puts and Dec-24 22 puts, with ...

Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the ...

Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Hims shares insights from its research to reveal the states providing the most comprehensive sex education curriculum and ...

While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children ...

Tropical Storm Rafael, which is expected to strengthen and may hit the Gulf Coast later this week, could further disrupt the IV solution supply chain if its path shifts towards Texas, where 4.4% of U.

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.